Beyond Air (XAIR) investor relations material

Executive summary

• Reported $1.8 million in revenue for the quarter ended June 30, 2026, matching the same period last year.

• Focused on expanding commercial reach for LungFit PH, preparing for Gen 2 system launch pending FDA approval, and strengthening global infrastructure.

• Entered a national group purchasing agreement with a major U.S. GPO, expanding access to nearly 2,000 hospitals and health systems.

• Regained compliance with Nasdaq's minimum bid price requirement after a 1-for-20 reverse stock split.

• International distribution network now covers over 45 countries, with regulatory milestones including CE mark approval in Europe.

Financial highlights

• Revenue for the quarter ended June 30, 2026, was $1.8 million, flat year-over-year.

• Gross margin improved to 13% from 9% year-over-year, marking the third consecutive quarter of positive gross profit.

• R&D expenses decreased to $2.0 million from $3.1 million year-over-year.

• SG&A expenses were $4.9 million, up from $4.7 million year-over-year.

• Net loss attributable to common stockholders was $7.9 million, or $11.00 per share, compared to $7.7 million, or $30.67 per share, in the prior year.

Outlook and guidance

• Reaffirmed 2026 revenue guidance of $8 million, representing ~15% growth over 2025, excluding Gen 2 LungFit PH revenue.

• 2027 revenue guidance of $16–$18 million, over 110% growth at midpoint, includes Gen 2 LungFit PH launch, subject to FDA approval.

• Management expects continued net losses and significant cash outflows for at least the next year, with substantial doubt about the ability to meet obligations without additional funding.

• Confident in achieving H2 revenue targets due to a doubled pipeline and international wins.

• Future capital needs depend on commercialization success, regulatory approvals, and clinical trial progress.